Welcome to our dedicated page for LEMAITRE VASCULAR SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LEMAITRE VASCULAR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LEMAITRE VASCULAR's regulatory disclosures and financial reporting.
LeMaitre Vascular director John James O'Connor reported grants of dividend equivalent rights linked to existing stock awards. On March 26, 2026, he acquired several small blocks of Dividend Equivalent Rights, each economically equivalent to one share of LeMaitre common stock.
The rights accrued on previously granted restricted stock unit and performance share unit awards from December 8, 2023, December 6, 2024, and December 10, 2025, and will vest proportionately with those underlying awards. These are compensation-related accruals rather than open‑market share purchases or sales.
LeMaitre Vascular director John A. Roush reported grants of dividend equivalent rights tied to prior equity awards. On March 26, 2026, he acquired several small fractional awards of Dividend Equivalent Rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued on restricted stock unit and performance share unit awards originally granted on December 8, 2023, December 6, 2024, and December 10, 2025, and they vest proportionately with those underlying awards. These are compensation-related accruals rather than open-market stock purchases or sales.
LEMAITRE VASCULAR INC director Lawrence J. Jasinski reported routine compensation-related grants of dividend equivalent rights. On March 26, 2026, he acquired several small fractional awards of dividend equivalent rights linked to existing restricted stock unit and performance share unit grants from December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying stock or performance awards. These are non-cash, derivative awards and do not represent any open-market share purchases or sales.
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported multiple awards of dividend equivalent rights on derivative securities. On March 26, 2026, he acquired several small grants of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards.
Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying equity awards granted in 2022, 2023, and 2024–2025. These are compensation-related accruals, with no open-market purchases or sales reported in this filing.
LeMaitre Vascular (LMAT) President and Director David B. Roberts reported compensation-related grants of dividend equivalent rights on derivative awards. On March 26, 2026, he acquired multiple small blocks of Dividend Equivalent Rights, each economically equal to one share of common stock and priced at $0.0000 per right.
The footnotes explain these rights accrued on previously granted restricted stock units and performance share units from awards dated December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025, and vest proportionately with those awards. No open‑market buys or sells were reported; this filing reflects routine equity-based compensation accrual rather than trading activity.
LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke reported seven acquisitions of Dividend Equivalent Rights on March 26, 2026. Each right is economically equivalent to one share of LeMaitre common stock and is tied to previously granted restricted stock unit and performance share unit awards from 2022, 2023, 2024 and 2025, vesting in step with those underlying awards. These entries reflect routine, compensation-related accruals rather than open-market trading.
LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular Chief Financial Officer Dorian Paul LeBlanc received additional dividend equivalent rights tied to existing restricted stock unit awards. On March 26, 2026, he was granted 2.0948 dividend equivalent rights related to an RSU award granted on March 10, 2025 and 2.6670 rights related to an RSU award granted on December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying RSUs. Following these awards, his holdings from these grants increased to 11.4217 and 2.6670 dividend equivalent rights, respectively.
LeMaitre Vascular’s Chairman and CEO, George W. LeMaitre, reported routine compensation-related awards rather than market trades. On March 26, 2026, he acquired several blocks of dividend equivalent rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued automatically on earlier restricted stock unit and performance share unit awards granted in December 2022, 2023, and 2024, and they will vest proportionately with those underlying awards. No open-market buying or selling occurred, and the transactions do not change cash holdings.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its holdings in LeMaitre Vascular Inc. The amendment states 0% beneficial ownership and 0 shares beneficially owned as of the filing, following an internal realignment on 01/12/2026 that disaggregated certain subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026. It affirms that no single third party holds more than 5% of the class among accounts aggregated by Vanguard.
LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares. He exercised options for 2,625 shares of common stock at an exercise price of $35.48 per share, then sold 2,625 shares at $108.50 per share, leaving 6,677 shares owned directly.